CoChat

Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on ‘Feels, Functions, Survives’. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the National Institutes of Health, a Patient Advocacy Organization, and a Regulatory Agency

Open access
Raghu, Ganesh, Ghazipura, Marya, Fleming, Thomas R., Aronson, Kerri I., Behr, Jürgen, Brown, Kevin K., Flaherty, Kevin R., Kazerooni, Ella A., Maher, Toby M., Richeldi, Luca, Lasky, Joseph A., Swigris, Jeffrey J., Busch, Robert, Garrard, Lili, Ahn, Dong-Hyun, Li, Ji, Puthawala, Khalid, Rodal, Gabriela, Seymour, Sally, Weir, Nargues, Danoff, Sonye K., Ettinger, Neil, Goldin, Jonathan, Glassberg, Marilyn K., Kawano-Dourado, Leticia, Khalil, Nasreen, Lancaster, Lisa, Lynch, David A., Mageto, Yolanda, Noth, Imre, Shore, Jessica E., Wijsenbeek, Marlies, Brown, Robert, Grogan, Daniel, Ivey, Dorothy, Golinska, Patrycja, Karimi-Shah, Banu, Martinez, Fernando J. · 2024 · American Journal of Respiratory and Critical Care Medicine
Cited by 92

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abstract

Background: Idiopathic pulmonary fibrosis (IPF) carries significant mortality and unpredictable progression, with limited therapeutic options. Designing trials with patient-meaningful endpoints, enhancing the reliability and interpretability of results, and streamlining the regulatory approval process are of critical importance to advancing clinical care in IPF. Methods: A landmark in-person symposium in June 2023 assembled 43 participants from the US and internationally, including patients with IPF, investigators, and regulatory representatives, to discuss the immediate future of IPF clinical trial endpoints. Patient advocates were central to discussions, which evaluated endpoints according to regulatory standards and the FDA’s ‘feels, functions, survives’ criteria. Results: Three themes emerged: 1) consensus on endpoints mirroring the lived experiences of patients with IPF; 2) consideration of replacing forced vital capacity (FVC) as the primary endpoint, potentially by composite endpoints that include ‘feels, functions, survives’ measures or FVC as components; 3) support for simplified, user-friendly patient-reported outcomes (PROs) as either components of primary composite endpoints or key secondary endpoints, supplemented by functional tests as secondary endpoints and novel biomarkers as supportive measures (FDA Guidance for Industry (Multiple Endpoints in Clinical Trials) available at: https://www.fda.gov/media/162416/download). Conclusions: This report, detailing the proceedings of this pivotal symposium, suggests a potential turning point in designing future IPF clinical trials more attuned to outcomes meaningful to patients, and documents the collective agreement across multidisciplinary stakeholders on the importance of anchoring IPF trial endpoints on real patient experiences—namely, how they feel, function, and survive. There is considerable optimism that clinical care in IPF will progress through trials focused on patient-centric insights, ultimately guiding transformative treatment strategies to enhance patients’ quality of life and survival.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1164/rccm.202312-2213so

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 92

Metadata

Authors
Raghu, G., Ghazipura, M., Fleming, T. R., Aronson, K. I., Behr, J., Brown, K. K., Flaherty, K. R., Kazerooni, E. A., Maher, T. M., Richeldi, L., Lasky, J. A., Swigris, J. J., Busch, R., Garrard, L., Ahn, D.-H., Li, J., Puthawala, K., Rodal, G., Seymour, S., Weir, N., Danoff, S. K., Ettinger, N., Goldin, J., Glassberg, M. K., Kawano-Dourado, L., Khalil, N., Lancaster, L., Lynch, D. A., Mageto, Y., Noth, I., Shore, J. E., Wijsenbeek, M., Brown, R., Grogan, D., Ivey, D., Golinska, P., Karimi-Shah, B., & Martinez, F. J.
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2024-03
Volume
209
Issue
6
Pages
647-669
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W4390580164
Cited by
92
References
31
FWCI
23.47
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on ‘Feels, Functions, Survives’. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the National Institutes of Health, a Patient Advocacy Organization, and a Regulatory Agency. https://app.cochat.ai/papers/10.1164/rccm.202312-2213so
The paper
Raghu, G., Ghazipura, M., Fleming, T. R., Aronson, K. I., Behr, J., Brown, K. K., Flaherty, K. R., Kazerooni, E. A., Maher, T. M., Richeldi, L., Lasky, J. A., Swigris, J. J., Busch, R., Garrard, L., Ahn, D.-H., Li, J., Puthawala, K., Rodal, G., Seymour, S., . . . Martinez, F. J. (2024). Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on ‘Feels, Functions, Survives’. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the National Institutes of Health, a Patient Advocacy Organization, and a Regulatory Agency. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.202312-2213so

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.